$NVO 0.56 Developing

Notable posts

• @StockSavvyShay bullish 816 eng

  10 STOCKS TRADING NEAR DECADE-LOW VALUATION MULTIPLES 1. $MSFT | Microsoft 2. $NFLX | Netflix 3. $MA | Mastercard 4. $MELI | MercadoLibre 5. $SE | Sea Limited 6. $PYPL | PayPal 7. $NVO | Novo Nordisk 8. $CRM | Salesforce 9. $ADBE | Adobe 10. $LULU | Lululemon

  view on X →
• @wallstengine neutral 425 eng

  Novo $NVO and Anthropic announced a collaboration to speed drug discovery, with Novo adopting Anthropic's models and Claude Science across R&D and software engineering. The partners will work on drug discovery problems identified by Novo's scientists and computational teams, building tools for biological reasoning and specific research workflows. CEO Mike Doustdar called it part of the push to become "the world's most AI-driven healthcare company," alongside Novo's existing AI partnerships. Dario Amodei framed the goal as compressing "a century's worth of biological and medical breakthroughs into a decade." No financial terms were disclosed.

  view on X →
• @StockSavvyShay bullish 418 eng

  $NVO and Anthropic are teaming up to use Claude across drug discovery, R&D and software engineering. The partnership is aimed at speeding biological research as Dario Amodei says goal is to compress “a century’s worth of biological and medical breakthroughs into a decade.” https://t.co/MkTe4SVPoc

  view on X →
• @wallstengine bearish 329 eng

  $NVO LONG-TERM PIPELINE PLAN FAILS TO IMPRESS INVESTORS Novo Nordisk’s long-term pipeline plan failed to impress investors, largely due to a lack of more specific near-term growth targets. Novo is targeting more than $23B in pipeline sales by 2035 and plans to launch more than five potential multi-blockbusters by the end of the decade. By 2030, Novo also expects: • At least 5 Ph3 programs in obesity and diabetes • At least 5 Ph3 programs in other therapeutic areas • More than 60M patients served globally • Broadly stable operating margins • Capacity to serve 10x more obesity patients with oral GLP-1s • 2026-30 revenue growth broadly in line with industry peers Management also acknowledged that competition has reached “an unprecedented level,” with almost every major pharma company now targeting obesity. Novo has already fallen behind Eli Lilly in the obesity market, is seeing early signs of semaglutide losing exclusivity in some markets, and faces Ozempic and Wegovy patent expirations in major markets early next decade. The company is also cutting another 4,000 jobs, bringing total restructuring-related reductions to roughly 13,000. CEO Mike Doustdar: “We need to work harder, and we will.”

  view on X →
• @Mr_Derivatives bullish 290 eng

  $NVO Watchlist for a big breakout here from a multi yr down trendline break? https://t.co/RzH7HoVRut

  view on X →
• @wallstengine mixed 274 eng

  Denmark’s 🇩🇰 central bank raised its 2026 GDP growth forecast to 4% from 1.8%, largely due to stronger-than-expected pharmaceutical exports tied to Novo. The bank said $NVO's U.S. sales and production were the main driver of extraordinary pharma growth in the first half. One caveat: much of the production happens outside Denmark, so the headline GDP numbers overstate the improvement in domestic prosperity. Q2 GDP rose 4.6% YoY, while real gross national income increased just 0.2%. Growth is expected to slow to 2.3% in 2027 and 2% in 2028 as the pharma boost moderates.

  view on X →
• @wallstengine neutral 237 eng

  Novo $NVO is open to considering a direct NYSE listing, replacing the ADR structure U.S. investors use today. CEO told the FT a direct listing could help raise Novo’s U.S. profile, where it generates more than half its revenue. The idea is not currently under active discussion https://t.co/A3j0pc5AF7

  view on X →
• @wallstengine neutral 223 eng

  NOVO NORDISK PLANS CHINA FILING FOR ORAL WEGOVY $NVO's CEO told Reuters the company plans to seek Chinese regulatory approval for its Wegovy weight-loss pill “very soon,” likely within a few months. The move comes as Novo races Eli Lilly in China’s obesity market, where Lilly has already submitted its oral GLP-1 application. Novo also faces pressure from semaglutide patent expiry in China and expected generic competition starting next year.

  view on X →